Cargando…

Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: a single-center analysis

PURPOSE: Treatment of refractory Hodgkin disease deserves specific considerations. Recently, alemtuzumab-BEAM has been introduced in allogeneic hematopoietic stem cell transplantation (HSCT) in these patients. METHODS: We retrospectively analyzed the outcome of 20 patients with relapsed/refractory H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rabitsch, W., Bojic, M., Wohlfarth, P., Leiner, M., Schörgenhofer, C., Kalhs, P., Schulenburg, A., Sillaber, C., Mitterbauer, M., Sperr, W. R., Jäger, U., Skrabs, K., Greinix, H., Hermann, A., Lamm, W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2016
Materias:	Original Article – Clinical Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4865538/ https://www.ncbi.nlm.nih.gov/pubmed/26920356 http://dx.doi.org/10.1007/s00432-016-2134-3

Ejemplares similares

Complete neurologic and cognitive recovery after plasmapheresis in a patient with chronic inflammatory demyelinating polyneuropathy after allogeneic hematopoietic stem cell transplantation
por: Vogl, Ursula, et al.
Publicado: (2016)

Incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: a retrospective cohort study
por: Harrison, Nicole, et al.
Publicado: (2015)

Adiponectin and resistin in acute and chronic graft-vs-host disease patients undergoing allogeneic hematopoietic stem cell transplantation
por: Robak, Oliver, et al.
Publicado: (2016)

Containment of a traceable COVID-19 outbreak among healthcare workers at a hematopoietic stem cell transplantation unit
por: Buchtele, N., et al.
Publicado: (2020)

Humoral immune response to tick-borne encephalitis vaccination in allogeneic blood and marrow graft recipients
por: Harrison, Nicole, et al.
Publicado: (2020)

Extracorporeal carbon dioxide removal as a bridge to lung transplantation in life-threatening hypercapnia
por: Riss, K, et al.
Publicado: (2014)

Autologous hematopoietic stem cell transplantation with concomitant SARS-CoV-2 infection
por: Knaus, Hanna A., et al.
Publicado: (2021)

Author Correction: Humoral immune response to tick-borne encephalitis vaccination in allogeneic blood and marrow graft recipients
por: Harrison, Nicole, et al.
Publicado: (2020)

Antigen-Specific Immunoadsorption With the Glycosorb® ABO Immunoadsorption System as a Novel Treatment Modality in Pure Red Cell Aplasia Following Major and Bidirectional ABO-Incompatible Allogeneic Hematopoietic Stem Cell Transplantation
por: Handisurya, Ammon, et al.
Publicado: (2020)

Determinants of gas exchange during extracorporeal CO(2) removal using a novel pump-driven venovenous gas exchange system in a minimally invasive setting
por: Hermann, A, et al.
Publicado: (2015)

Evaluation of efficacy of alemtuzumab in 5 patients with aplastic anemia and/or myelodysplastic neoplasm
por: Füreder, Wolfgang, et al.
Publicado: (2016)

A bi‐centric experience of extracorporeal carbon dioxide removal (ECCO(2)R) for acute hypercapnic respiratory failure following allogeneic hematopoietic stem cell transplantation
por: Wohlfarth, Philipp, et al.
Publicado: (2021)

Sustained hematologic remission after discontinuation of sutimlimab treatment in patients with cold agglutinin disease
por: Gelbenegger, Georg, et al.
Publicado: (2022)

Exposure-response analysis of alemtuzumab in pediatric allogeneic HSCT for nonmalignant diseases: the ARTIC study
por: Achini-Gutzwiller, Federica R., et al.
Publicado: (2023)

Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation
por: Ogonek, Justyna, et al.
Publicado: (2016)

Tick-Borne Encephalitis Specific Lymphocyte Response after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Humoral Immunity after Vaccination
por: Harrison, Nicole, et al.
Publicado: (2021)

Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT
por: Burns, D M, et al.
Publicado: (2016)

Critically ill patients with cancer: chances and limitations of intensive care medicine—a narrative review
por: Schellongowski, Peter, et al.
Publicado: (2016)

Mixed T Cell Chimerism After Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia Using an Alemtuzumab-Containing Regimen Is Shaped by Persistence of Recipient CD8 T Cells
por: Grimaldi, Francesco, et al.
Publicado: (2017)

Alemtuzumab
por: Tridente, Giuseppe
Publicado: (2013)

The assessment of platelet function by thromboelastometry as a point‐of‐care test to guide Intercept‐treated platelet support in hemato‐oncological patients and hematopoietic stem cell transplantation recipients
por: Leitner, Gerda C., et al.
Publicado: (2020)

Alemtuzumab for Multiple Sclerosis
por: Willis, Mark D., et al.
Publicado: (2016)

Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts
por: Valent, Peter, et al.
Publicado: (2023)

Improving Outcomes After Allogeneic Hematopoietic Cell Transplantation for Hodgkin Lymphoma in the Brentuximab Vedotin Era
por: Hegerova, Livia, et al.
Publicado: (2017)

Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma in Switzerland, 20 years of experience: 2001–2020
por: Simeunovic, Helena, et al.
Publicado: (2022)

Alemtuzumab for the treatment of multiple sclerosis
por: Willis, Mark D, et al.
Publicado: (2015)

Population Pharmacokinetics of Alemtuzumab (Campath) in Pediatric Hematopoietic Cell Transplantation: Towards Individualized Dosing to Improve Outcome
por: Admiraal, Rick, et al.
Publicado: (2019)

Microbiologic Diagnostic Workup of Acute Respiratory Failure with Pulmonary Infiltrates after Allogeneic Hematopoietic Stem Cell Transplantation: Findings in the Era of Molecular- and Biomarker-Based Assays
por: Wohlfarth, Philipp, et al.
Publicado: (2018)

Extracorporeal membrane oxygenation in adult patients with hematologic malignancies and severe acute respiratory failure
por: Wohlfarth, Philipp, et al.
Publicado: (2014)

Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era
por: Porpaczy, Edit, et al.
Publicado: (2021)

Reappraising the Role of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Hodgkin’s Lymphoma: Recent Advances and Outcomes
por: Al-Juhaishi, Taha, et al.
Publicado: (2022)

Allogeneic hematopoietic stem cell transplantation in non‐Hodgkin lymphoma in Switzerland, 30 years of experience: Sooner is better
por: Rebmann, Ekaterina, et al.
Publicado: (2022)

Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents
por: Faisal, Muhammad Salman, et al.
Publicado: (2023)

Alemtuzumab in Covid era
por: Iovino, Aniello, et al.
Publicado: (2021)

Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis
por: Alping, Peter, et al.
Publicado: (2021)

Allogeneic hematopoietic cell transplantation in patients ⩾70 years: which patients may benefit?
por: Haen, S P, et al.
Publicado: (2016)

Influence of Acute and Chronic Graft-Versus-Host Disease on Persistence of Antibodies against Measles, Mumps, Rubella and Varicella in the First Year after Autologous or Allogeneic Hematopoietic Stem Cell Transplantation
por: Harrison, Nicole, et al.
Publicado: (2023)

Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML
por: Valent, Peter, et al.
Publicado: (2019)

BTK inhibition is a potent approach to block IgE‐mediated histamine release in human basophils
por: Smiljkovic, D., et al.
Publicado: (2017)

Outcomes in relapsed Hodgkin's lymphoma treated with autologous and allogeneic hematopoietic cell transplantation at the Pontificia Universidad Católica de Chile
por: Ramirez, Pablo, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_gfah5nff7n1j98d2mv2iv39vjg